|Volume 6 Issue 59 Published - 14:00 UTC 08:00 EST 28-Feb-2004 Next Update - 14:00 UTC 08:00 EST 29-Feb-2004||Editor: Susan K. Boyer, RN
© Vidyya., Inc.
All rights reserved.
Single drug for cholesterol, blood pressure approved
The U.S. Food and Drug Administration has approved the Pfizer drug Caduet, a dual-therapy drug for high cholesterol and high blood pressure, the company says.
This new drug is a combination of two of Pfizer's largest products, Lipitor for high cholesterol and Norvasc for hypertension. The company estimates that while 30 million Americans suffer from both conditions, more than 90% of these people have not achieved targeted cholesterol or blood pressure levels. A single pill contains the cholesterol drug Lipitor (atorvastatin calcium) and the blood pressure medication Norvasc (amlodipine besylate).
The two conditions are leading factors for heart attack and stroke, and some 30 million people in the United States have both, Pfizer says.
The news brought positive motion in Pfizer's stock, however, some brokerage houses see significant potential for this new drug to cannibalize existing Pfizer Lipitor and Norvasc sales.